Recognizing Subsets of Triple-Negative Breast Cancer
Tiffany A. Traina, MD, a medical oncologist at Weill Cornell Medicine, discusses the current treatment landscape for patients with triple-negative breast cancer.
Tiffany A. Traina, MD, a medical oncologist at Weill Cornell Medicine, discusses the current treatment landscape for patients with triple-negative breast cancer (TNBC).
Traina says it is very encouraging right now for patients with TNBC, while there is an increasing recognition of subsets within the disease. With the recent FDA approval of olaparib (Lynparza) and positive results from a phase III trial in patients with BRCA mutations, Traina says it is more evident than ever that there are many germline mutations in TNBC that must be recognized for successful treatment of patients with TNBC.
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
